Global – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 05 Apr 2023 16:29:05 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 American Diversified Holdings Corporation (ADHC) Enters into a Comprehensive Alliance with Green Globe International Group Inc. (GGII), Hempacco (HPCO) and GGII Subsidiary Green Star Labs, Inc. https://mjshareholders.com/american-diversified-holdings-corporation-adhc-enters-into-a-comprehensive-alliance-with-green-globe-international-group-inc-ggii-hempacco-hpco-and-ggii-subsidiary-green-star-labs-inc/ Wed, 05 Apr 2023 16:29:05 +0000 https://cannabisfn.com/?p=2972963

Ryan Allway

April 5th, 2023

News, Top News


Relationship Set to Accelerate ADHC’s Brands into the $59 Billion CBD Market

Del Mar, California–(Newsfile Corp. – April 5, 2023) – American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce today that the company, through it’s brands UNIVERSAL WELLNESS and Amazon vendor ROLLSCHOICE, has reached a comprehensive alliance with GGII’s leading group of a companies in the CBD and Hemp sector. ADHC’s agreement with Green Globe Intl Group (OTC Pink: GGII), Hempacco (NASDAQ: HPCO) and GGII’s operating subsidiary Green Star Labs provides for a broad range of services and interrelated business activity.

The GGII/HEMPACCO/GREENSTAR group has entered into this alliance with ADHC and will collaborate as outlined below:

  1. Formulation, manufacturing, private label, inventory management, packaging and shipment logistics with be provided by Green Star Labs under the Universal Wellness and Rolls Choice Brand.
  2. Jointly design a line of CDB, Dietary Supplements and Cosmetic products to be offered through ADHC’ e-commerce platform www.UniversalWellnessShop.com.
  3. Introduce and negotiate endorsement agreements with social media influencers and noted HipHop/Rap luminaries. Hempacco currently has relationships deals with Snoop Dogg Brands, rap artist Rick Ross, Hemp Hop Smokables and Cheech and Chong, Hemp Cigarettes.
  4. Parties have agreed to a financial partnership including share issuances, line of credit for product inventory, capital formation and addition of future management.
  5. Parties have agreed to assess the develop of ADHC existing brand and future products under development, including products sold under the ROLLS CHOICE BRAND of cannabis adhesive pens and UNIVERSAL WELLNESS lifestyle and CBD products.

This alliance is set to springboard ADHC’S branded products into the rapidly growing CDB market sector. A recent report by Market Research Future (MRFR) indicated the CDB market is expected to reach over $59 billion by 2030 an 18% CAGR.
see Cannabidiol (CBD) Market Size Worth USD 59.3 Billion by (globenewswire.com)

“This alliance with ADHC’s Universal Wellness and Rolls Choice brands is great opportunity for us to build revenues with a great partner,” commented Sandro Piancone, CEO of GGII and HPCO. “We look forward to hitting the ground running for a long term mutually beneficial alliance.”

“The GGII/HPCO team is truly brilliant alliance partner for ADHC, we can now focus on pushing our brands to the forefront of the CBD and Cannabis markets with a manufacturing and brand building partner that is a dream come true for our shareholder,” commented ADHC management.

Hempacco

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_001full.jpg

About Hempacco (NASDAQ: HPCO)
Hempacco Co., Inc.’s goal is Disrupting Tobacco’s™ nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff™ functional hemp cigarette and rolling paper brand.

Hempacco’s operating segments include:

  1. Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks
  2. Smokable technology development
  3. The Real Stuff™ brand of functional smokables and rolling paper
  4. Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross
  5. Snoop Dogg Joint Venture of Hemp-Derived Products

Learn more at www.hempacco.com.

Order products at www.realstuffsmokables.com.

About HempBox Vending
HempBox Vending offers a kiosk solution for smart vending technology to sell quickly moving consumer goods, including but not limited to nutraceuticals, CBD, hemp, herb, and spice smokables.

About Green Globe International, Inc. (OTC Pink: GGII)
Green Globe International is a Fast-Moving Consumer Goods incubator and holding company of intellectual property, products, and companies that better people’s lives by helping them feel and look better inside and out.

GGII

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_002full.jpg

Green Globe International (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., (NASDAQ: HPCO) Disrupting Tobacco’s™ $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. a vending and advertising company, Hempacco Paper Company, Inc., producing The Real Stuff Hemp Smokables and hemp paper smoking products like blunts, tubes, and cones, Cali Vibes, Inc. manufacturing cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivering cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners, StickIt USA, Inc., manufacturing a line of cannabinoid sticks, and HPDG, LLC a partnership with Snoop Dogg to develop hemp-derived consumer goods products.

Green Star Labs

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_003full.jpg

Green Globe is publicly traded under the ticker symbol (OTC Pink: GGII). It continues to look for best-in-class companies, products, and patents to create Fast Moving Consumer Goods and channels to sell them, including retail automation and advertising platforms.

Universal Wellness

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_004full.jpg

ABOUT ADHC/UNIVERSAL WELLNESS/ROLLS CHOICE
ADHC is a publicly traded holding company trading under the ticker symbol (OTC Pink: ADHC).
ADHC is currently developing two web-based branded businesses.

  1. Universal Wellness
    http://www.UniversalWellnessShop.com (UWS)
    (UWS) is a wellness and lifestyle ecommerce site focused upon providing innovative products, news and the latest health care developments.
  2. Rolls Choice™ is a Southern California based manufacturer, distributer and ecommerce company selling an all-natural Adhesive Glue and application device sold off AMAZON.com and through its own website.

The Pens come in 1 ml, 2 ml and 100 pen packs. Rolls Choice™ has significant brand awareness in the cannabis industry and boasts over 80,000 followers on Twitter and Instagram. Recently over 12,000 adhesive pens have been manufactured and sold. The adhesive is made of Food Grade Premium ingredients. Rolls Choice Adhesive Pen is Flavorless, Colorless, Tasteless and Stainless. It is used to seal cannabis and tobacco rolled products including blunts, joints, cigars and hand rolled cigarettes in a sterile manner allowing for long lasting adhesive qualities. The proprietary brush tip pen is recommended for precision. RC sells direct to smoke shops, dispensaries and direct to consumers through its e-commerce site. Through the companies multi year history sales over 12,000 adhesive pens and been manufactured and sold by Rolls Choice. see (USPTO ROLLS CHOICE 97278083).

Rolls Choice

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/161275_70688a16d49a19c0_005full.jpg

ROLLS CHOICE™ has over 80,000 social media followers which will be introduced to ADHC social media platforms on Twitter, Instagram, Facebook, and TikTok. This relationship will establish a very strong presence providing brand awareness to potential customers and shareholders as the Universal Wellness/Rolls Choice business relationship develops and revenues grow.
Website: www.Rollschoiceadhesive.com
Email: rollschoicerepresentative619@gmail.com
Twitter: https://www.twitter.com/rollschoice
Instagram: https://www.instagram.com/rollschoiceadhesivepen

In addition to the adhesive pen, RC has numerous other cannabis related products being developed that will be introduced as a result of this Acquisition agreement.

Shareholders, customers and other interested parties can find product offerings by searching AMAZON under these UPC codes or clicking this link: https://tinyurl.com/yc2y543u UPC codes B0B1BTNW4Q and B0B2R3D2TS.

Amazon.com: Rolls Choice™ Adhesive Pen (25, 1ml): Arts, Crafts & Sewing

ROLLS CHOICE™ has a pending trademark with the USPTO under the application number 972978083.
LITIGATION UPDATE
ADHC has filed suit in The Eight Judicial Circuit Court, Clark County, Nevada case Number A-21-843-670, seeking the cancellation of 330,000,000 (330 MM) shares of common stock. On January 6, 2023 the court granted the motion for default. Its is anticipated the court will be issuing the formal order soon on a scheduled hearing date on April 17th, 2023.
Granting the default judgment is the final legal step before all litigation is resolved.
Currently, ADHC capitalization structure is as follows:
Shares Outstanding: 1.1 billion
Shares Restricted: 600 million
Shares in the Float: 504 million

Investor Contact:
Ernest Remo
Chairman/CEO
ernestremo@san.rr.com
Tel: 858-259-4534
TWITTER: @ADHCManagement. This Twitter page is the only official twitter page for ADHC.

Information contained herein includes forward-looking statements.

SAFE HARBOR
These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different performance or achievements expressed. You should not place undue reliance on these statements since they involve known and unknown risks. Any forward-looking statements reflect the current view with respect to future events and subject to uncertainties.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Optimi Health Dealer’s License Granted by Health Canada https://mjshareholders.com/optimi-health-dealers-license-granted-by-health-canada/ Mon, 07 Feb 2022 15:04:16 +0000 https://www.cannabisfn.com/?p=2937155

Optimi Health to become a global leader in all-natural psilocybin production

VANCOUVER, BC (February 7, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Optimi Labs Inc., a wholly-owned subsidiary of Optimi Health Corp, been granted a Dealer’s License by Health Canada.

The Dealer’s License allows for possession, production, assembling, sale, and delivery of psilocybin within the regulated framework set forth by Health Canada. Optimi will now launch vertically integrated operations at its facility in Princeton, B.C. Once fully commercialized, Optimi’s purpose-built, 10,000 sq. ft. EU GMP-compliant research and production facility will be dedicated to cultivating, extracting, and processing the highest-grade all-natural psilocybin in North America. Guiding Optimi’s stringent research and drug development process, the Company’s GMP and EU-GMP-compliant facility will expand its domestic and global reach in compliance with Health Canada regulations and favourable international regulatory regimes.

“This is a proud and exciting moment for all of us at Optimi,” exclaimed Bryan Safarik, COO and Director of Optimi. He continued, “We purposely overbuilt this facility surpassing clean room pharma grade specifications, allowing us to grow and process the purest, most consistent, safest, and efficacious mushrooms in the industry. I have always believed in our ability to be a Canadian leader in the production of natural-grade psilocybin, so I am truly grateful for all the hard work, insight, and continued effort to get this world-class facility commissioned.” Safarik also praised Health Canada’s leadership role in working with Canadian drug producers as they continue to expand the science and safety of therapeutic psilocybin mushrooms through research and clinical trials.

As noted in the recently filed annual financials, as of September 30, 2021, $8,586,465 CAD in cumulative expenditures were incurred in connection with the construction of the combined 20,000 sq. ft. facilities. Optimi’s Dealer’s License EU GMP-compliant facility contains an impressive Region III, Schedule 8 security level vault capable of securing 1,250kg of psilocybin which carries an approximate value of $53MM CDN. Other features include an Argus environmental control system which provides software and hardware features for real-time monitoring and optimization, advanced HVAC equipment and controls, fire suppression, clean room technology, 700KW backup electrical power systems, robust chain-link fencing with smart system technology including perimeter intrusion detection, wireless gate access and magnetic locks.

Optimi is poised to become the only large-scale Canadian manufacturer, and the premier supplier, of all-natural psilocybin therapies to patients, research groups, universities, licensed clinics and holders of other Dealer’s Licenses and Section 56 exemptions in Canada. While the prescription model of psilocybin delivery is dependent on further clinical trial data from the industry, Optimi will be able to supply patients by way of their physicians and the Special Access Program today. The Company has begun outreach to potential psilocybin clients in Canada and is actively seeking commercial opportunities for its products in select markets with favourable regulatory regimes.

With Health Canada’s recent amendment of the Special Access Program, physicians will be able to request patient access to restricted psychoactive substances like psilocybin and MDMA for psychedelic-assisted therapy. Optimi is taking an active leadership role in finding solutions for the ongoing Canadian mental health crisis, including access to psilocybin for therapeutic purposes. Furthermore, Optimi is committed to being proactive concerning education about the safety and efficacy of psychedelic medicines and this is exemplified through its initial phase 1 dosing study.

“Optimi is focused on providing safe, pure and reliable psychedelic products for all those in need,” said Bill Ciprick, CEO. “Achieving our approved Dealer’s License is a significant milestone in our journey to becoming a leader in the psychedelic industry. We look forward to providing further communications over the coming weeks as production begins, and our 2022 growth strategy is deployed.”

Additionally, Optimi will host an official ribbon-cutting event, late spring, to showcase its state-of-the-art facility and team leadership. The event will be coordinated around all public health protocols established during that time to ensure the health and safety of everyone involved.

On Behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: [email protected]ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

]]>
Top Marijuana Stocks To Buy In November? 2 Global Companies For List Right Now https://mjshareholders.com/top-marijuana-stocks-to-buy-in-november-2-global-companies-for-list-right-now/ Fri, 19 Nov 2021 12:45:30 +0000 https://marijuanastocks.com/?p=50419 Investing In The Global Cannabis Market In 2021

The post Top Marijuana Stocks To Buy In November? 2 Global Companies For List Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

]]>

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>Top Marijuana Stocks To Buy In November? 2 Global Companies For List Right Now

<!– Click –>

]]>
Halo Labs to Expand Globally and Acquire Bophelo Bioscience https://mjshareholders.com/halo-labs-to-expand-globally-and-acquire-bophelo-bioscience/ Mon, 17 Jun 2019 21:01:59 +0000 https://www.cannabisfn.com/?p=2576416

Ryan Allway

June 17th, 2019


Cannabis Industry in Lesotho, Africa to Become Gateway to EU Cannabis Markets

Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce that it has entered into a non-binding letter of intent (LOI) for the proposed acquisition of Bophelo Bioscience & Wellness (Pty) Ltd (“Bophelo”) (the “Transaction”). The Transaction is expected to strengthen the Company’s position in Lesotho, Africa, a country quickly becoming the continent’s export gateway to the global cannabis market. Lesotho is the first African country to grant medical marijuana licenses for cultivation and patient use and is making strides toward becoming the worldwide export hub for cannabis. Halo’s planned acquisition of Bophelo brings together two socially-minded companies on a shared mission to better the communities in Lesotho.

Halo’s initial partnership with Bophelo included operation of the 5-hectare cultivation and production site and purchase of its entire production in exchange for a 20% equity stake and a royalty on cannabis sales. In a growing consumer market, Halo now intends to purchase the entire issued share capital of Bophelo for 40,786,667 common shares in the capital of Halo (approximately USD $18.4M or CAD $24.7M).

Supreme Cannabis (TSX: FIRE) and Canopy Growth Corporation (TSX: WEED) made significant investments in Lesotho recently with Supreme Cannabis making a CAD $10M strategic investment in Medigrow Lesotho (Pty) in exchange for a 10% ownership interest in that company, and Canopy Growth Corporation acquiring 100% of DaddyCann Lesotho (Pty) Ltd for CAD $28.8M.

This Transaction is expected to strengthen Halo’s position in a region strategically set to become the international breadbasket of Good Agricultural and Collecting Practice (GACP) and EU Good Manufacturing Practices (GMP)-grade cannabis isolates and distillates. GACP and GMP designations demonstrate Halo’s capability to grow and manufacture at scale while adhering to high-quality standards and enables distribution to European and international pharmaceutical and nutraceutical companies in these attractive and growing markets.

Beyond providing a source of low-cost cannabis inputs and products for Europe and other regions, Africa as a continent boasts a strong consumer market. According to New Frontier, there are over 83 million annual cannabis consumers on the continent and the current market is estimated at USD $37.3 billion in combined legal and illegal sales out of the total USD $344.4 billion worldwide. This emerging opportunity will be unlocked with increased cannabis decriminalization and legalization policies, such as neighboring South Africa; which in 2018 approved private use and decriminalized possession, a market which according to the March 2019 Prohibition Partners Africa Report is now expected to be worth USD $1.851 billion by 2023.

Kiran Sidhu, the CEO of Halo Labs, commented, “The high-altitude, low-humidity climate and access to water, as well as low cost utility, tax, and labor rates mean cannabis in Lesotho can be cultivated naturally at a very competitive cost. While most of the licenses issued to date restrict cultivation to 2-3 hectares and indoor or greenhouse growing, Bophelo operates one of the largest sites in Lesotho at 5 hectares. The state has also given Bophelo preliminary approval to expand up to 200 hectares and has indicated they would consider granting permission for outdoor growing from 2019 onwards, following consultation with the INCB (International Narcotics Control Board). Bophelo has secured this site with a 20-year lease and option to renew for an additional 30 years.”

Once fully operational on the initial 5 hectare site, Bophelo intends to harvest GACP cultivated cannabis approximately twice per annum and will have the potential to produce approximately 4.6M grams of high quality EU GMP cannabis concentrate per annum.

Mr. Sidhu continued, “We anticipate EU GMP cannabis concentrate would be exported to the European market at an estimated price of USD $10 per gram while our FOB Lesotho all-in cost ready for export would not exceed USD $2 per gram. We expect the initial planting to occur in November and to complete our first harvest by the second quarter of 2019. Bophelo will also give Halo Labs an international platform for our innovative products like the DabTabs™ Dablets, the first ASTM C373-18 certified doseable cannabis product.”

Halo continues to solidify its reputation as a leader in cannabis oil and concentrates and is now the first U.S. based publicly traded company to make an investment into Lesotho. Upon closing of the Transaction, Halo will expand its global footprint and be one of the first cannabis companies in the world to have products and technology carried across the EU, the United States, and Africa.

The Chairman and non-executive director of Bophelo, Ms. Louisa Mojela, stated, “The acquisition of Bophelo by Halo Labs gives me great hope for the future of Africa’s cannabis industry. I am glad to be working with Halo’s executive team, too. Together we will strengthen Lesotho’s position as the breadbasket for Europe, Australia, and other global markets.” Ms. Mojela is among Africa’s most successful business personalities and a prominent citizen of Lesotho. She has been recognized by countless international organizations for her contributions to business, women, and impoverished communities winning an All Africa Business Leaders award by CNBC in 2016.

Halo’s acquisition of Bophelo will further solidify the Company’s strategic vision in addition to exemplifying its support of social responsibility initiatives. For example, the land leased by Bophelo is held by a non-profit trust that benefits the community. 10% (ten percent) of Bophelo’s pre-tax profits will go to this trust and be given back to the people of Lesotho. Both Ms. Mojela and Mr. Sidhu are like-minded about social impact and equity. Through support from the trust, Ms. Mojela has founded and built a school on Bophelo’s premises and Mr. Sidhu is personally donating computers for the school’s students. Ms. Mojela commented, “The social benefits of our public-private partnership are extremely important to me. Halo shares that commitment and these values will differentiate us from our competitors.”

Chairman of Halo Labs, G. Scott Paterson, summed up anticipated benefits from the transaction, “The proposed acquisition of Bophelo is game changing for Halo and important for the global cannabis economy. We are enthusiastic about the Lesotho opportunity and operating a scale cultivation and production facility for the international export of oil and concentrates. We expect a lift both to revenue and profit and are looking forward to delivering these financial results to our shareholders.”

Completion of the Transaction is subject to, among other things, the negotiation and execution of a mutually agreeable definitive acquisition agreement and related documents and the satisfaction or waiver of any conditions precedent to the consummation of the Transaction (including the receipt of any requisite regulatory and third-party approvals).

ABOUT HALO LABS

Halo is a cannabis extraction company that develops and manufactures quality cannabis oils and concentrates, which are the fastest growing segments in the cannabis industry. Halo is a global leader in cannabis oil and concentrates and has expertise across as major cannabis manufacturing processes, leveraging proprietary processes and products, and has produced over 4.0M grams of oils and concentrates since inception. The forward-thinking company is led by a strong management team with deep industry knowledge and blue-chip experience. The Company is currently operating in California and Oregon as well as Nevada with our partner Just Quality and in Lesotho with the Bophelo strategic partnership. With a consumer-centric focus, Halo will continue to market innovative branded and private label products across multiple product categories.

ABOUT BOPHELO BIOSCIENCE

Bophelo Bioscience is based in the Kingdom of Lesotho, Southern Africa and is the holder of one of a limited number of licenses issued in Lesotho for the production of medicinal cannabis products. Situated in proximity 70 kilometers to the capital city of Maseru, the Company’s operating site is an ideal location with ample labor, free water, flat land area, and low crime rates. The favorable high altitude, low humidity climate provides clean and organic growing conditions within the pristine mountainous region. With the motto “Sechaba se tlisa lerou” (community brings wealth), Bophelo highlights the value of community and empowerment of the Basotho people with a focus on the development of women and youth.

ABOUT LESOTHO

Lesotho is the first African country to legalize the cultivation and manufacturing of medicinal cannabis, becoming one of the most sought-after locations for cannabis operations in the world. The country has issued a limited number of licenses since legalization in 2016 and has been exporting cannabis since early 2018.

For further information regarding Halo, see Halo’s disclosure documents on SEDAR at www.sedar.com.

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Halo’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Halo’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, statements regarding the Transaction (including the terms thereof, the entering into of definitive documentation and closing conditions), the receipt of regulatory approvals, the distribution and sale of Halo and Bophelo and the size and growth of the global and regional cannabis market generally.

By identifying such information and statements in this manner, Halo is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Halo has made certain assumptions. Although Halo believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Halo does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Halo or persons acting on its behalf is expressly qualified in its entirety by this notice.

Copyright Business Wire 2019

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>